Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
about
Optimizing tumor immune response through combination of radiation and immunotherapy.Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy.Radiotherapy for Oligometastatic Lung Cancer.From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers.Radiotherapy: the key to immunotherapy ignition?EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.Trial watch: Immune checkpoint blockers for cancer therapy.Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance.Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences.The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.Radiotherapy and checkpoint inhibitors: a winning new combination?Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules.Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study.Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer.Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma.Utility of stereotactic ablative radiotherapy/stereotactic body radiation therapy in the setting of oligometastatic non-small cell lung cancer.Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.Immunotherapy in the Asiatic population: any differences from Caucasian population?Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors.Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios.Effects of radiation on the metastatic process.Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.Need for prospective collection of experience and repeated samples in esophageal squamous cell carcinoma.Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibitionDNA repair defects and implications for immunotherapyA case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumabQ57168562The current state of oligometastatic and oligoprogressive non-small cell lung cancerPrognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New EvidencesDurvalumab in NSCLC: latest evidence and clinical potentialToxicity of radiation and immunotherapy combinations
P2860
Q38614781-63E8B9FA-7AB1-4598-8B6C-2FB705B189D8Q41475564-2B190B48-B03F-4F0C-89B3-D5DC94CFD692Q42109226-AD0C969E-6169-42D1-9E0C-5AC990E45099Q45952214-852A5937-0728-45B3-BC58-228748A077B6Q46708524-279BF8B3-036C-4BFF-967A-016EC87CAE1CQ47161023-E325E251-64B1-4AC9-B797-ADCA07C35FA9Q47214499-73264699-55B4-4914-A19F-73752D15B461Q47393365-41C1E572-D6C0-4BE5-A719-85BDD48B9698Q47551609-8F1584F9-DE12-4A4D-B39E-65AB616FFEF4Q47821832-EC762264-1FE4-48D2-B7E8-DE0829341342Q47899811-924EB607-CA48-4416-83BA-8A0CE965AB7AQ49478699-669178EB-3B19-4616-A543-68CAFEDB518CQ50044559-B4DA0C9D-97D0-4CAF-A988-5826500E1599Q50103704-E7C8BD9E-62B8-477D-8A38-D2845C9E953AQ52584384-3C19E639-E0AC-486E-854C-9DBAA36BCD7AQ52602002-72C95561-39EF-4F15-921F-DDA03849A806Q52718920-44FB1056-61E2-496F-BA7C-596C38564505Q53045959-EB69E262-CC80-4D1C-B28A-9C294A27D526Q54942438-9EAB184E-9A1C-42BB-8B5C-97E7DAC15B8CQ55065259-19C3A4F6-3FE6-46C2-A993-E876A67D43D1Q55079845-80CE4AEF-5C84-422F-BED6-51772C7338D0Q55084146-EFC48C70-BF9E-4A75-B162-F5506FC0BF0FQ55240069-D0C7E0F5-EBFF-4C37-AA11-2BB8F4866E2AQ55286402-07B58AB7-4C69-48DB-8A29-4A9309D1E96CQ55287125-A42ED865-0B9F-4E9B-B658-7FBD62026BE2Q55312983-3C55CA56-354E-4AC2-B20E-8813DB1889B1Q55314300-88089D1B-02E8-40AC-B110-446E7D2E03BAQ55322253-7C25178C-E924-49FB-84D3-F0FFE60F5C99Q55401509-B059A6CB-D3B9-41FC-B80E-D97FD98108DCQ55417312-08D21115-C131-4A8B-8685-D06243B6F6A5Q55491553-AC70D261-15A6-42C0-B08A-8E9EEDC5863DQ55711391-4EE92806-D5E1-47ED-A3F8-0FD48FE84C93Q56892343-9E9BEE08-74F4-4318-9696-0CF8F349EFEBQ57057014-31AA6988-B362-42A0-B9F1-E6D4B0B869AAQ57074555-FDE622AF-2264-4B6D-B59A-FB3A0928C748Q57168562-989A3CAC-806B-49D4-94BC-968E7CFF070DQ57172942-B7E364D8-7352-4044-8CC3-4E4D2F5D9D28Q57191808-11E2085F-E6E1-4FE7-A2C2-73664A25371DQ57816055-5270E820-06A6-476A-9751-24DF9CE2ED64Q58119196-DCFD7DA7-45B7-4489-B5EE-27590483BC08
P2860
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Previous radiotherapy and the ...... the KEYNOTE-001 phase 1 trial.
@en
type
label
Previous radiotherapy and the ...... the KEYNOTE-001 phase 1 trial.
@en
prefLabel
Previous radiotherapy and the ...... the KEYNOTE-001 phase 1 trial.
@en
P2093
P2860
P1433
P1476
Previous radiotherapy and the ...... the KEYNOTE-001 phase 1 trial
@en
P2093
Aaron E Lisberg
Darlene Veruttipong
Edward B Garon
Jonathan W Goldman
Krikor Bornazyan
Silvia C Formenti
P2860
P304
P356
10.1016/S1470-2045(17)30380-7
P577
2017-05-24T00:00:00Z